APM
NTLA icon

Avidity Partners Management’s Intellia Therapeutics NTLA Stock Holding History

Avidity Partners Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27M Hold
75,000
– – 0.2% 34
2026
Q1 		$962K Buy
+75,000
New +$955K 0.19% 37
2025
Q3 		– Sell
-232,000
Closed -$2.18M – 56
2025
Q2 		$2.18M Buy
+232,000
New +$1.91M 0.43% 48
2024
Q3 		– Sell
-170,000
Closed -$3.8M – 95
2024
Q2 		$3.8M Buy
+170,000
New +$4.05M 0.16% 75
2024
Q1 		– Sell
-447,434
Closed -$13.6M – 101
2023
Q4 		$13.6M Buy
447,434
+68,334
+18% +$1.96M 0.5% 55
2023
Q3 		$12M Sell
379,100
-16,755
-4% -$650K 0.48% 61
2023
Q2 		$16.1M Sell
395,855
-21,145
-5% -$857K 0.56% 60
2023
Q1 		$15.5M Sell
417,000
-221,200
-35% -$8.68M 0.52% 59
2022
Q4 		$22.3M Sell
638,200
-360,900
-36% -$17.2M 0.48% 48
2022
Q3 		$55.9M Sell
999,100
-126,094
-11% -$7.82M 1.14% 32
2022
Q2 		$58.2M Buy
1,125,194
+735,119
+188% +$37.3M 1.34% 25
2022
Q1 		$28.3M Buy
+390,075
New +$33M 0.59% 45
2021
Q4 		– Sell
-251,000
Closed -$33.7M – 107
2021
Q3 		$33.7M Sell
251,000
-129,000
-34% -$19.5M 0.75% 45
2021
Q2 		$61.5M Buy
+380,000
New +$29.6M 1.66% 21
2021
Q1 		– Sell
-303,000
Closed -$16.5M – 114
2020
Q4 		$16.5M Buy
+303,000
New +$11M 0.54% 54
2020
Q3 		– Sell
-418,178
Closed -$8.79M – 81
2020
Q2 		$8.79M Buy
+418,178
New +$7.1M 0.56% 47

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Avidity Partners Management's NTLA Position: Q2 2026 in Review

Avidity Partners Management held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 75,000 shares worth $1.27M. The position accounts for 0.2% of the portfolio, ranked #34.

Avidity Partners Management first reported a position in NTLA in Q2 2020 and has held it in 16 quarters since. The position peaked at $61.5M in Q2 2021. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Avidity Partners Management held 75,000 shares of Intellia Therapeutics worth $1.27M as of Q2 2026.
  • Avidity Partners Management left its Intellia Therapeutics share count unchanged in Q2 2026.
  • Intellia Therapeutics made up 0.2% of Avidity Partners Management's portfolio in Q2 2026, its #34 holding.
  • Avidity Partners Management first reported a position in Intellia Therapeutics in Q2 2020 and has held it in 16 quarters since.
  • Avidity Partners Management's Intellia Therapeutics position peaked at $61.5M in Q2 2021.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.